<p>德国耶拿，2026 年 5 月 1 日（全球新闻通讯社）——InflaRx N.V.（纳斯达克：IFRX），一家通过靶向补体系统开创抗炎疗法的生物制药公司，今天宣布公司将于 2026 年 5 月 7 日市场开盘前发布 2026 年第一季度的财务和运营结果。没有计划召开电话会议。</p>
<p><strong><em>关于 InflaRx</em></strong></p>
<p>InflaRx（纳斯达克：IFRX）是一家生物制药公司，通过应用其专有的抗 C5a 和抗 C5aR 技术，开创抗炎疗法，发现、开发和商业化对补体激活因子 C5a 及其受体 C5aR 的高效且特异的抑制剂。C5a 是一种强大的炎症介质，参与多种炎症疾病的进展。InflaRx 的主要项目是 izicopan，一种口服给药的小分子抑制剂，能够通过 C5a 受体抑制 C5a 诱导的信号传导，在 1 期和 2a 期临床研究中显示出良好的药代动力学/药效学特征以及治疗潜力。公司正在开发 izicopan 用于治疗多种炎症疾病，包括脓疱性汗腺炎。InflaRx 还开发了 vilobelimab，这是一种新型的、静脉给药的首创抗 C5a 单克隆抗体，能够选择性结合游离 C5a，并在多项临床研究中显示出疾病修饰的临床活性和耐受性。</p>
<p>InflaRx 成立于 2007 年，集团在德国耶拿和慕尼黑以及美国密歇根州安阿伯设有办公室和子公司。有关更多信息，请访问 www.inflarx.de。InflaRx GmbH（德国）和 InflaRx Pharmaceuticals Inc.（美国）是 InflaRx N.V.的全资子公司（统称为 InflaRx）。</p>
<p><strong><em>联系方式：</em></strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>InflaRx N.V.</strong></td>
<td><strong>MC Services AG</strong></td>
</tr>
<tr>
<td>Jan Medina, CFA</td>
<td></td>
</tr>
<tr>
<td>投资者关系副总裁</td>
<td></td>
</tr>
<tr>
<td>电子邮件：IR@inflarx.de</td>
<td>Katja Arnold, Laurie Doyle, Dr. Regina Lutz</td>
</tr>
<tr>
<td>电子邮件：inflarx@mc-services.eu</td>
<td></td>
</tr>
<tr>
<td>欧洲：+49 89-210 2280</td>
<td></td>
</tr>
<tr>
<td>美国：+1-339-832-0752</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明。除历史事实声明外的所有声明均为前瞻性声明，通常以 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“估计”、“相信”、“预测”、“潜在” 或 “继续” 等术语表示。前瞻性声明在本稿的多个地方出现，可能包括关于我们意图、信念、预测、展望、分析和当前期望的声明，涉及我们未来临床试验的成功，特别是 vilobelimab 治疗其他致残或危及生命的炎症指征，包括急性呼吸窘迫综合症（ARDS）；潜在的战略交易或合作，包括 izicopan 或 vilobelimab 在 PG 方面的潜在合作；我们未来临床试验的成功，以及这些临床结果是否会反映之前进行的临床前研究和临床试验的结果；vilobelimab、izicopan 及其他产品候选者的临床前研究和临床试验的时间、进展和结果，以及研究或试验的启动和完成时间及相关准备工作的时间，试验结果可用的时间，试验的成本以及我们研究和开发项目的一般情况；我们与监管机构的互动，涉及临床试验结果和潜在的监管批准路径，包括与我们提交 GOHIBIC（vilobelimab）的生物制剂许可证申请相关的内容，以及我们获得和维持 vilobelimab 或 GOHIBIC（vilobelimab）在任何指征下的全面监管批准的能力；FDA 或任何可比的外国监管机构是否会接受或同意我们临床试验的数量、设计、规模、实施或执行，包括任何拟议的主要或次要终点；我们利用专有的抗 C5a 和抗 C5aR 技术发现和开发治疗补体介导的免疫和炎症疾病的疗法的能力；我们保护、维护和执行 vilobelimab、izicopan 及其他产品候选者的知识产权保护的能力及其保护范围；我们的制造能力和战略，包括我们制造方法和流程的可扩展性和成本，以及我们制造方法和流程的优化，以及我们继续依赖现有第三方制造商的能力，以及我们为计划中的未来临床试验和 vilobelimab 的商业供应及成品 GOHIBIC（vilobelimab）聘请额外第三方制造商的能力；我们对费用、持续损失、未来收入、资本需求的估计，以及我们获得额外融资的需求或能力；我们在临床测试产品候选者或一旦获得批准的商业销售中对责任索赔的防御能力；如果我们的任何产品候选者获得监管批准，我们遵守和满足持续义务及持续监管审查的能力；我们在寻求市场批准或商业化时遵守现行和未来立法的能力；我们的未来增长和竞争能力，这取决于我们保留关键人员和招聘额外合格人员的能力；以及我们在 C5a 和 C5aR 抑制剂开发或我们行业中的竞争对手的发展和预测；以及在我们定期向 SEC 提交的文件中 “风险因素” 标题下描述的风险、不确定性和其他因素。这些声明仅在本新闻稿发布之日有效，并涉及已知和未知的风险、不确定性及其他重要因素，这些因素可能导致我们的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过于依赖，我们不承担更新这些前瞻性声明的义务，即使未来有新信息可用，法律要求的情况除外。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1UQTJOU00zTlRjM016UTBJekl4T1RReU5ERT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1UQTJOU00zTlRjM016UTBJekl4T1RReU5ERT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGQ2MTliNzAtYzgyYy00MjJlLTkwYmUtYzVjYTNmMjEyYzUwLTEyMDU3OTQtMjAyNi0wNS0wMS1lbg==/tiny/InflaRx-N-V-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGQ2MTliNzAtYzgyYy00MjJlLTkwYmUtYzVjYTNmMjEyYzUwLTEyMDU3OTQtMjAyNi0wNS0wMS1lbg==/tiny/InflaRx-N-V-.png"/></p>

IFRX

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

<p>InflaRx N.V. 将于 2026 年 5 月 7 日在市场开盘前公布其 2026 年第一季度的财务和运营结果。该公司专注于针对补体系统的抗炎治疗，主要项目包括 izicopan 和 vilobelimab。此次公告没有安排电话会议。InflaRx 成立于 2007 年，在德国和美国运营，专注于开发各种炎症疾病的治疗方案</p>

<p>JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the first quarter 2026 on May 7, 2026, before the market opens. No conference call is planned.</p>
<div class="lb-trans"><p>德国耶拿，2026 年 5 月 1 日（全球新闻通讯社）——InflaRx N.V.（纳斯达克：IFRX），一家通过靶向补体系统开创抗炎疗法的生物制药公司，今天宣布公司将于 2026 年 5 月 7 日市场开盘前发布 2026 年第一季度的财务和运营结果。没有计划召开电话会议。</p>
</div><p><strong><em>About InflaRx</em></strong></p>
<div class="lb-trans"><p><strong><em>关于 InflaRx</em></strong></p>
</div><p>InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.</p>
<div class="lb-trans"><p>InflaRx（纳斯达克：IFRX）是一家生物制药公司，通过应用其专有的抗 C5a 和抗 C5aR 技术，开创抗炎疗法，发现、开发和商业化对补体激活因子 C5a 及其受体 C5aR 的高效且特异的抑制剂。C5a 是一种强大的炎症介质，参与多种炎症疾病的进展。InflaRx 的主要项目是 izicopan，一种口服给药的小分子抑制剂，能够通过 C5a 受体抑制 C5a 诱导的信号传导，在 1 期和 2a 期临床研究中显示出良好的药代动力学/药效学特征以及治疗潜力。公司正在开发 izicopan 用于治疗多种炎症疾病，包括脓疱性汗腺炎。InflaRx 还开发了 vilobelimab，这是一种新型的、静脉给药的首创抗 C5a 单克隆抗体，能够选择性结合游离 C5a，并在多项临床研究中显示出疾病修饰的临床活性和耐受性。</p>
</div><p>InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</p>
<div class="lb-trans"><p>InflaRx 成立于 2007 年，集团在德国耶拿和慕尼黑以及美国密歇根州安阿伯设有办公室和子公司。有关更多信息，请访问 www.inflarx.de。InflaRx GmbH（德国）和 InflaRx Pharmaceuticals Inc.（美国）是 InflaRx N.V.的全资子公司（统称为 InflaRx）。</p>
</div><p><strong><em>Contacts:</em></strong></p>
<div class="lb-trans"><p><strong><em>联系方式：</em></strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>InflaRx N.V.</strong></td>
<td><strong>MC Services AG</strong></td>
</tr>
<tr>
<td>Jan Medina, CFA<br/>Vice President, Head of Investor Relations<br/>Email: IR@inflarx.de</td>
<td>Katja Arnold, Laurie Doyle, Dr. Regina Lutz<br/>Email: inflarx@mc-services.eu<br/>Europe: +49 89-210 2280<br/>U.S.: +1-339-832-0752</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>InflaRx N.V.</strong></td>
<td><strong>MC Services AG</strong></td>
</tr>
<tr>
<td>Jan Medina, CFA</td>
<td></td>
</tr>
<tr>
<td>投资者关系副总裁</td>
<td></td>
</tr>
<tr>
<td>电子邮件：IR@inflarx.de</td>
<td>Katja Arnold, Laurie Doyle, Dr. Regina Lutz</td>
</tr>
<tr>
<td>电子邮件：inflarx@mc-services.eu</td>
<td></td>
</tr>
<tr>
<td>欧洲：+49 89-210 2280</td>
<td></td>
</tr>
<tr>
<td>美国：+1-339-832-0752</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><strong>FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the success of our future clinical trials for vilobelimab's treatment of other debilitating or life-threatening inflammatory indications, including acute respiratory distress syndrome, or ARDS; potential strategic transactions or collaborations, including a potential partnership of izicopan, or vilobelimab for PG; the success of our future clinical trials for izicopan, and whether such clinical results will reflect results seen in previously conducted pre-clinical studies and clinical trials; the timing, progress and results of pre-clinical studies and clinical trials of vilobelimab, izicopan and any other of our product candidates and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our biologics license application submission for GOHIBIC (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or GOHIBIC (vilobelimab) for any indication; whether the FDA, or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases; our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection; our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval, our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and future legislation in seeking marketing approval or commercialization; our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors described under the heading “Risk Factors” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。除历史事实声明外的所有声明均为前瞻性声明，通常以 “可能”、“将”、“应该”、“期望”、“计划”、“预期”、“能够”、“打算”、“目标”、“项目”、“估计”、“相信”、“预测”、“潜在” 或 “继续” 等术语表示。前瞻性声明在本稿的多个地方出现，可能包括关于我们意图、信念、预测、展望、分析和当前期望的声明，涉及我们未来临床试验的成功，特别是 vilobelimab 治疗其他致残或危及生命的炎症指征，包括急性呼吸窘迫综合症（ARDS）；潜在的战略交易或合作，包括 izicopan 或 vilobelimab 在 PG 方面的潜在合作；我们未来临床试验的成功，以及这些临床结果是否会反映之前进行的临床前研究和临床试验的结果；vilobelimab、izicopan 及其他产品候选者的临床前研究和临床试验的时间、进展和结果，以及研究或试验的启动和完成时间及相关准备工作的时间，试验结果可用的时间，试验的成本以及我们研究和开发项目的一般情况；我们与监管机构的互动，涉及临床试验结果和潜在的监管批准路径，包括与我们提交 GOHIBIC（vilobelimab）的生物制剂许可证申请相关的内容，以及我们获得和维持 vilobelimab 或 GOHIBIC（vilobelimab）在任何指征下的全面监管批准的能力；FDA 或任何可比的外国监管机构是否会接受或同意我们临床试验的数量、设计、规模、实施或执行，包括任何拟议的主要或次要终点；我们利用专有的抗 C5a 和抗 C5aR 技术发现和开发治疗补体介导的免疫和炎症疾病的疗法的能力；我们保护、维护和执行 vilobelimab、izicopan 及其他产品候选者的知识产权保护的能力及其保护范围；我们的制造能力和战略，包括我们制造方法和流程的可扩展性和成本，以及我们制造方法和流程的优化，以及我们继续依赖现有第三方制造商的能力，以及我们为计划中的未来临床试验和 vilobelimab 的商业供应及成品 GOHIBIC（vilobelimab）聘请额外第三方制造商的能力；我们对费用、持续损失、未来收入、资本需求的估计，以及我们获得额外融资的需求或能力；我们在临床测试产品候选者或一旦获得批准的商业销售中对责任索赔的防御能力；如果我们的任何产品候选者获得监管批准，我们遵守和满足持续义务及持续监管审查的能力；我们在寻求市场批准或商业化时遵守现行和未来立法的能力；我们的未来增长和竞争能力，这取决于我们保留关键人员和招聘额外合格人员的能力；以及我们在 C5a 和 C5aR 抑制剂开发或我们行业中的竞争对手的发展和预测；以及在我们定期向 SEC 提交的文件中 “风险因素” 标题下描述的风险、不确定性和其他因素。这些声明仅在本新闻稿发布之日有效，并涉及已知和未知的风险、不确定性及其他重要因素，这些因素可能导致我们的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就存在重大差异。鉴于这些风险、不确定性和其他因素，您不应对这些前瞻性声明过于依赖，我们不承担更新这些前瞻性声明的义务，即使未来有新信息可用，法律要求的情况除外。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1UQTJOU00zTlRjM016UTBJekl4T1RReU5ERT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTA2NSM3NTc3MzQ0IzIxOTQyNDE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGQ2MTliNzAtYzgyYy00MjJlLTkwYmUtYzVjYTNmMjEyYzUwLTEyMDU3OTQtMjAyNi0wNS0wMS1lbg==/tiny/InflaRx-N-V-.png" alt="" original-src="https://ml.globenewswire.com/media/NGQ2MTliNzAtYzgyYy00MjJlLTkwYmUtYzVjYTNmMjEyYzUwLTEyMDU3OTQtMjAyNi0wNS0wMS1lbg==/tiny/InflaRx-N-V-.png"/></p>

InflaRx to Report First Quarter 2026 Results on May 7, 2026 | IFRX Stock News

StockTitan

InflaRx NV

Invesco Nasdaq Biotechnology ETF

InflaRx 将于2026年5月7日公布 2026 年第一季度财务业绩 | IFRX 股票新闻